Izabella Ryguła

Ms. Izabella Ryguła

Medical University of Silesia, Katowice, Śląskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
Izabella RygułaIzabella Ryguła
Izabella Ryguła
WPWojciech Pikiewicz
Wojciech Pikiewicz
KKKonrad Kaminiów
Konrad Kaminiów
Acne vulgaris is a widespread a chronic inflammatory dermatosis that affects millions of people around the world, which has a significant influence on patients’ standard of living. The progression of this dermatosis results in the appearance of inflammatory and non-inflammatory changes, and, in severe cases, disfiguring scars and hyperpigmentation. The aetiopathogenesis of acne is complex. It involves a complex interaction of many different factors, both endo- and exogenous in their effect on the hair and sebaceous unit. Genetic predisposition, hormones, the skin and gut microbiome, psychological stress, air pollutants, aggressive facial products, and certain medications are cited as factors influencing acne formation. The link between nutrition and acne is extensively debated for many years and is still relatively controversial. Diet is commonly recognised to have a direct relationship with certain biochemical markers and the transcription of genes related to sebaceous gland function, and the proliferation of bacteria and inflammation that encourage the progression of the disease. In this review, the authors take a closer look at the existing scientific reports on the involvement of nutrition in the development of acne vulgaris.

Verified
Journal Article
Open access
PDF file
Izabella RygułaIzabella Ryguła
Izabella Ryguła
WPWojciech Pikiewicz
Wojciech Pikiewicz
BGBENIAMIN Oskar GRABAREK
BENIAMIN Oskar GRABAREK
MWMichał Wójcik
Michał Wójcik
KKKonrad Kaminiów
Konrad Kaminiów
Dermatoses are an increasingly common problem, particularly in developed countries. The causes of this phenomenon include genetic factors and environmental elements. More and more scientific reports suggest that the gut microbiome, more specifically its dysbiosis, also plays an important role in the induction and progression of diseases, including dermatological diseases. The gut microbiome is recognised as the largest endocrine organ, and has a key function in maintaining human homeostasis. In this review, the authors will take a close look at the link between the gut–skin axis and the pathogenesis of dermatoses such as atopic dermatitis, psoriasis, alopecia areata, and acne. The authors will also focus on the role of probiotics in remodelling the microbiome and the alleviation of dermatoses.

13 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Izabella RygułaIzabella Ryguła
Izabella Ryguła
WPWojciech Pikiewicz
Wojciech Pikiewicz
KKKonrad Kaminiów
Konrad Kaminiów
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus disrupting the JAK-STAT pathway. This pathway plays a role in key cellular processes such as the immune response and cell growth. This feature is used in the treatment of patients with rheumatological, gastroenterological and hematological diseases. Recently, it has been discovered that JAK-STAT pathway inhibitors also show therapeutic potential against dermatological diseases such as atopic dermatitis, psoriasis, alopecia areata and acquired vitiligo. Studies are underway to use them in the treatment of several other dermatoses. Janus kinase inhibitors represent a promising class of drugs for the treatment of skin diseases refractory to conventional therapy. The purpose of this review is to summarize the latest knowledge on the use of JAKi in dermatological treatment.

Verified
Journal Article
Open access
PDF file
TSTomasz Sirek
Tomasz Sirek
ASAgata Sirek
Agata Sirek
PBPrzemysław Borawski
Przemysław Borawski
Izabella RygułaIzabella Ryguła
Izabella Ryguła
KKKatarzyna Król-Jatręga
Katarzyna Król-Jatręga
BGBENIAMIN Oskar GRABAREK
BENIAMIN Oskar GRABAREK
This study aimed to assess the expression profile of messenger RNA (mRNA) and microRNA (miRNA) related to the dopaminergic system in five types of breast cancer in Polish women. Patients with five breast cancer subtypes were included in the study: luminal A (n = 130), luminal B (n = 196, including HER2−, n = 100; HER2+, n = 96), HER2+ (n = 36), and TNBC (n = 43); they underwent surgery, during which tumor tissue was removed along with a margin of healthy tissue (control material). The molecular analysis included a microarray profile of mRNAs and miRNAs associated with the dopaminergic system, a real-time polymerase chain reaction preceded by reverse transcription for selected genes, and determinations of their concentration using enzyme-linked immunosorbent assay (ELISA). The conducted statistical analysis showed that five mRNAs statistically significantly differentiated breast cancer sections regardless of subtype compared to control samples; these were dopamine receptor 2 (DRD2), dopamine receptor 3 (DRD3), dopamine receptor 25 (DRD5), transforming growth factor beta 2 (TGF-β-2), and caveolin 2 (CAV2). The predicted analysis showed that hsa-miR-141-3p can regulate the expression of DRD2 and TGF-β-2, whereas hsa-miR-4441 is potentially engaged in the expression regulation of DRD3 and DRD5. In addition, the expression pattern of DRD5 mRNA can also be regulated by has-miR-16-5p. The overexpression of DRD2 and DRD3, with concomitant silencing of DRD5 expression, confirms the presence of dopaminergic abnormalities in breast cancer patients. Moreover, these abnormalities may be the result of miR-141-3P, miR-16-5p, and miR-4441 activity, regulating proliferation or metastasis.

28 December 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
KKKonrad Kaminiów
Konrad Kaminiów
Izabella RygułaIzabella Ryguła
Izabella Ryguła
Justyna PaprockaJustyna Paprocka
Justyna Paprocka
Ataxia is a movement disorder that manifests during the execution of purposeful movements. It results from damage to the structures of the cerebellum and its connections or the posterior cords of the spinal cord. It should be noted that, in addition to occurring as part of many diseases, pediatric ataxia is a common symptom in neurometabolic diseases. To date, there are more than 150 inherited metabolic disorders that can manifest as ataxia in children. Neuroimaging studies (magnetic resonance imaging of the head and spinal cord) are essential in the diagnosis of ataxia, and genetic studies are performed when metabolic diseases are suspected. It is important to remember that most of these disorders are progressive if left untreated. Therefore, it is crucial to include neurometabolic disorders in the differential diagnosis of ataxia, so that an early diagnosis can be made. Initiating prompt treatment influences positive neurodevelopmental outcomes.

14 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Izabella RygułaIzabella Ryguła
Izabella Ryguła
VRVioletta Rosiek
Violetta Rosiek
BKBeata Kos-Kudła
Beata Kos-Kudła
Inflammation is a hallmark of cancer and contributes to tumour initiation, progression, and therapeutic resistance. Among inflammatory mediators, interleukin-1β (IL-1β) and interleukin-6 (IL-6) are central cytokines linking innate immune responses with oncogenic signalling networks. This narrative review summarizes current experimental and clinical evidence regarding the role of IL-1β and IL-6 in carcinogenesis, with particular emphasis on gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). We discuss the molecular pathways associated with these cytokines, their interactions within the tumour microenvironment, and their contribution to tumour proliferation, angiogenesis, immune modulation, metastatic dissemination, and resistance to anticancer therapies. Particular attention is given to GEP-NENs, in which chronic inflammation and cytokine dysregulation may influence tumour behaviour, systemic inflammatory activity, and clinical outcomes. Accumulating evidence suggests that IL-6 may represent a promising exploratory biomarker associated with tumour burden, histological grade, disease progression, and systemic inflammation, whereas IL-1β appears to be more closely linked to local inflammatory signalling, microenvironmental remodelling, and potential susceptibility mechanisms. However, current evidence in GEP-NENs remains limited by small study cohorts, heterogeneous patient populations, variable analytical methodologies, and the lack of prospective validation. Further translational and clinical investigations are warranted to determine whether cytokine-based biomarkers and therapeutic modulation of inflammatory pathways may expand current diagnostic, prognostic, and therapeutic approaches in GEP-NENs.